Cargando…
Systemic therapy and COVID19: Immunotherapy and chemotherapy
As the novel severe acute respiratory syndrome coronavirus-2 related pandemic - Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not...
Autores principales: | Gulati, Shuchi, Muddasani, Ramya, Gustavo Bergerot, Paulo, Pal, Sumanta K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762713/ https://www.ncbi.nlm.nih.gov/pubmed/33451934 http://dx.doi.org/10.1016/j.urolonc.2020.12.022 |
Ejemplares similares
-
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019) -
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017) -
Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma
por: Staehler, Michael, et al.
Publicado: (2021) -
Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020) -
Renal cell carcinoma: An update for the practicing urologist
por: Pal, Sumanta K., et al.
Publicado: (2015)